Gilead Stock Tops 3 GARP Picks Trading On More Measured Valuations

AI related stocks are drawing much of the market’s attention right now, which can leave solid, profitable companies trading on valuations that still look reasonable. That is exactly where a Growth at a Reasonable Price approach can help you focus on businesses with positive earnings profiles and measured risk, without chasing the most crowded trades. This article looks at how the current AI driven rotation interacts with fundamental metrics like P/E and PEG ratios, and highlights three stocks from our GARP screener that appear positively exposed to the latest news and market sentiment shifts.

Belden (BDC)

Overview: Belden is a US based industrial technology company that supplies high performance networking, cabling, and automation solutions that move and manage data for customers in areas like data centers, factories, broadband networks, and smart buildings.

Market Cap: US$3.9b

Belden provides exposure to data infrastructure, automation, and OT/IT convergence without paying AI stock premiums, as the company focuses on networking hardware, software, and services that sit behind digital transformation projects. Earnings have grown in recent years, analysts expect further expansion, and the current P/E around 16.7x is below many electronics peers, which may appeal to GARP investors looking for growth at a moderate price. At the same time, Belden carries a high level of debt and recent commentary highlights pressure on margins and return on invested capital. The key question is whether new acquisitions and solution based offerings can offset those risks and support the next phase of the company’s strategy.

Belden’s earnings story and mid teens P/E could be masking a more complex trade off between growth, debt and margin pressure. It is worth scanning the 5 key rewards and 1 important warning sign

Daktronics (DAKT)

Overview: Daktronics is a long established US company that designs and manufactures LED scoreboards, large video walls, and digital signage systems used in sports venues, retail, transportation hubs, and other commercial spaces around the world.

Operations: Daktronics generates most of its revenue from Live Events (US$321.1m), High School Park and Recreation (US$183.3m), and Commercial (US$180.8m), with additional contributions from Transportation (US$76.7m) and International (US$76.9m) segments.

Market Cap: US$923.2m

Daktronics gives you exposure to the shift toward digital displays and smart city infrastructure at a time when capital is crowding into AI stocks, leaving some profitable hardware and software suppliers trading on more measured expectations. The company has recently moved from losses to profitability, with high quality earnings and an order backlog that supports future revenue. At the same time, relatively low Return on Equity, higher risk funding through external borrowings, and a new management team introduce execution risk. For GARP investors, the real question is whether the current valuation, improving margins, and index reclassification into growth focused benchmarks fully reflect the company’s prospects.

Daktronics’ shift from losses to profitability, together with its order backlog and index reclassification, suggests the story is still developing. The real hinge may sit inside the analysis report for Daktronics

Gilead Sciences (GILD)

Overview: Gilead Sciences is a large US biopharmaceutical company that discovers, develops, and sells medicines for serious conditions such as HIV, viral hepatitis, cancer, fungal infections, and COVID-19 across the United States, Europe, and other international markets.

Operations: Gilead Sciences generates about US$29.7b in revenue from discovering, developing, and commercializing medicines, with sales concentrated in the United States (US$21.1b) and supported by Europe (US$5.1b) and the rest of the world (US$3.5b).

Market Cap: US$169.2b

Gilead Sciences is often considered by GARP investors as offering a mix of established profitability and potential pipeline-driven upside, with reported high quality earnings, a 31% net margin, and a dividend around 2.44% supporting its large HIV and oncology franchises. Recent approvals and reported positive data for Trodelvy in first line triple negative breast cancer and for long acting HIV regimens indicate additional potential areas of focus, while some analysts view the stock as trading meaningfully below their estimated fair value based on their own future cash flow models. The trade off for investors to consider is a relatively high debt load, slower forecast revenue growth than the broader US market according to some analyst estimates, and heavy reliance on HIV therapies, which adds regulatory and patent risk that may be weighed against the company’s cash generation and expanding pipeline.

Gilead Sciences’ high quality earnings, 31% net margin and 2.44% dividend may not fully reflect what comes next, particularly given its HIV focus and oncology pipeline in play. It is therefore worth scanning the analyst forecasts for Gilead Sciences

The three stocks in this article are only a starting point, as the full Growth at a Reasonable Price (GARP) Stocks screener uncovers 10 more companies with similarly compelling Growth at a Reasonable Price profiles and narratives. Use Simply Wall St to identify, filter, and analyze the specific catalysts, fundamentals, and valuation markers that matter most so you can focus on the highest conviction GARP ideas across your watchlist.

Take Control of Your Investment Journey

If Gilead Sciences or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond AI?

Some stock stories move from quiet accumulation to sudden breakout before anyone notices. Use these fresh ideas while they are still under the radar for now, get in early.

• Target resilient compounders with steady balance sheets before momentum sends them flying by screening a curated list of solid balance sheet and fundamentals (47 results) that is built for durability, not hype.
• Ride potential upside in companies building the rails for tomorrow's automation wave by scanning our hand picked 33 robotics and automation stocks powering factories, logistics, and smarter infrastructure.
• Explore early tailwinds in cash generative miners while valuations still look reasonable using a tightly curated 33 elite gold producer stocks focused on scale, costs, and balance sheet strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com